Skip to content

US · ATTO · BIOTECHNOLOGY

Attovia Therapeutics, Inc. (ATTO) intrinsic value and stock valuation

$22.14as of 2026-09-18 · Mkt cap 957.42M

Data updated · price as of 2026-09-18

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Attovia Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ATTO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ATTO’s statements →

Attovia Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Carlos, CA, US attovia.com

How the business is doing

Fiscal 2025–2024, USD

Revenue
$0.00
20252024
Net income
-$-39.8T
20252024
Free cash flow
-$-36.81T
20252024
Total equity
$62.1T
20252024

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2024, USD
FYFY
Revenue$1.35T$0.00
Operating income-$-67.16T-$-41.55T
Net income-$-60.63T-$-39.8T
EPSd-$-1.41M-$-924.98K
Operating cash flow-$-59.2T-$-35.04T
Capital expenditure-$-2.31T-$-1.77T
Free cash flow-$-61.51T-$-36.81T
Total assets$165.9T$76.7T
Total debt$5.26T$0.00
Net debt-$-34.93T-$-30.63T
Total equity$150.8T$62.1T
Cash and short-term investments$152.3T$69.3T
Income statement
FYFY
Revenue$1.35T$0.00
Cost of revenue$804B$313B
Gross profit$546B-$-313B
Research and development expenses$54.2T$33.9T
Selling, general and administrative expenses$13.6T$7.38T
Other expenses$0.00$0.00
Operating expenses$67.7T$41.2T
Cost and expenses$68.5T$41.6T
Interest income$6.63T$3.44T
Interest expense$0.00$0.00
Depreciation and amortization$804B$313B
Ebitda-$-66.36T-$-41.24T
Operating income-$-67.16T-$-41.55T
Total other income/expenses, net$6.53T$1.75T
Income before tax-$-60.63T-$-39.8T
Income tax expense$0.00$0.00
Net income-$-60.63T-$-39.8T
Weighted average shares outstanding$43T$43T
Weighted average diluted shares outstanding$43T$43T
Balance sheet
FYFY
Cash and short-term investments$152.3T$69.3T
Net receivables$0.00$0.00
Inventory$0.00$0.00
Total current assets$156.3T$72.5T
Property, plant and equipment, net$7.87T$3.23T
Goodwill and intangible assets$0.00$0.00
Long-term investments$404B$607B
Total non-current assets$9.6T$4.23T
Total assets$165.9T$76.7T
Accounts payable$3.55T$4.14T
Short-term debt$1.92T$0.00
Deferred revenue$450B$0.00
Total current liabilities$11T$7.72T
Long-term debt$3.34T$0.00
Deferred revenue, non-current$0.00$0.00
Total non-current liabilities$4.1T$6.87T
Capital lease obligations$3.34T$0.00
Total liabilities$15.1T$14.6T
Common stock$1B$1B
Retained earnings-$-111.01T-$-50.38T
Accumulated other comprehensive income (loss)$99B$67B
Total equity$150.8T$62.1T
Total investments$112.5T$39.3T
Total debt$5.26T$0.00
Net debt-$-34.93T-$-30.63T
Cash flow statement
FYFY
Net income-$-60.9T-$-45.05T
Depreciation and amortization$804B$313B
Stock-based compensation$0.00$0.00
Change in working capital$276B$1.54T
Accounts receivable$0.00$0.00
Inventory$0.00$0.00
Accounts payable$180B$1.72T
Net cash provided by operating activities-$-59.2T-$-35.04T
Investments in property, plant and equipment-$-2.31T-$-1.77T
Acquisitions, net$0.00$0.00
Net cash used for investing activities-$-73.46T-$-39.8T
Common stock issued$142T$82.9T
Common stock repurchased$0.00$0.00
Dividends paid$0.00$0.00
Net cash used for financing activities$142T$82.7T
Net change in cash$9.56T$30.6T
Cash at end of period$40.2T$30.6T
Operating cash flow-$-59.2T-$-35.04T
Capital expenditure-$-2.31T-$-1.77T
Free cash flow-$-61.51T-$-36.81T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Attovia Therapeutics, Inc.

        A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

        CEO
        Tao Fu
        Employees
        44
        Beta
        0.00

        Explore

        Frequently asked questions

        What is the intrinsic value of Attovia Therapeutics, Inc. (ATTO)?

        Attovia Therapeutics, Inc. (ATTO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ATTO undervalued?

        ATTO trades at a price of $22.14 (Sep 19, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.